ATOS - Latest News
Atossa Therapeutics, Inc. (ATOS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $27.7M. Beta to the broader market is 1.27.
The article list below shows the most recent ATOS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ATOS Headlines
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
prnewswire.com - Oct 9, 2026
Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter CVRs entitle
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
prnewswire.com - Sep 29, 2026
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net procee
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
prnewswire.com - Sep 24, 2026
Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways SEATTLE, Sept. 24, 2
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
prnewswire.com - Aug 7, 2026
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
prnewswire.com - Jul 28, 2026
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest p
How News Affects ATOS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ATOS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ATOS news questions
- What is the latest ATOS news headline?
- The most recent ATOS headline (Oct 9, 2026) is "Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ATOS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ATOS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ATOS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.